• Explore /
  • Poster
  • / B-F1RST: Assessment of novel blood-based biomarkers in patients with first-line advanced or metastatic NSCLC receiving atezolizumab monotherapy.

B-F1RST: Assessment of novel blood-based biomarkers in patients with first-line advanced or metastatic NSCLC receiving atezolizumab monotherapy.

Abstract Poster

Authors

Edward Kim

Edward S. Kim

Levine Cancer Institute, Charlotte, NC

Edward S. Kim , Mark A. Socinski , Shaker R. Dakhil , Niklas J. Mackler , Nadeem Ikhlaque , Tarek Mekhail , Fabio Volterra , Christian Antoine El Khoury , Joan H. Schiller , Michaela L. Tsai , Fadi Hayek , Jeffrey D. Neidhart , Brian Hunis , Sylvia Hu , Sarah M. Paul , David S. Shames , See-Chun Phan , Cindy Yun , Vamsidhar Velcheti

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02848651

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS9103)

DOI

10.1200/JCO.2017.35.15_suppl.TPS9103

Abstract #

TPS9103

Poster Bd #

425b

Abstract Disclosures

Similar Posters

First Author: Thierry Landre

First Author: Heather A. Wakelee

First Author: Leisha A. Emens

First Author: Vassiliki Papadimitrakopoulou